288 results about "Cell cycle" patented technology

The invention relates to the field of molecular targeted therapy, and discloses an application of an SLC16A5 (MCT6) small-molecule inhibitor MCT6-Ai7-2 in preparation of a medicine for treating acute myeloid leukemia (AML). The inhibitor takes an SLC16A5 protein structure predicted by Alphafold as a target spot, and is obtained through compound database screening, molecular docking and druggability optimization. An in-vitro experiment proves that MCT6-Ai7-2 can remarkably inhibit proliferation of AML cell lines such as U937 and MOLM-13, induce cell apoptosis and retard a cell cycle, has an inhibiting effect on a primary AML patient specimen and is relatively low in toxicity to normal cells; in-vivo experiments show that the compound is effective and has good safety in AML model mice. In addition, the MCT6-Ai7-2 and the vinca can be combined to synergistically enhance the inhibition effect on vinca drug-resistant cells, and by reducing the expression of anti-apoptotic protein MCL-1, the activation of pro-apoptotic factors BIM and tBID is promoted to play a role. The invention provides a novel targeting drug and strategy for treatment of AML (especially drug-resistant or recurrent patients).

The invention discloses an application of LDLR in screening or preparing a medicine for treating acute myelogenous leukemia, the expression level of the LDLR in acute myelogenous leukemia cells is detected for the first time so as to characterize the conditions of proliferation, apoptosis, cycle and the like of the acute myelogenous leukemia cells, and the LDLR is taken as a target spot; by knocking down the expression quantity of the LDLR, the proliferation of acute myelogenous leukemia cells can be inhibited, the apoptosis of the acute myelogenous leukemia cells can be promoted, the cycle of the acute myelogenous leukemia cells can be retarded in the S phase, the in-vitro proliferation of the acute myelogenous leukemia cells can be accurately and effectively inhibited, and the application prospect is wide. A new thought and a new direction are provided for screening or preparing the medicine for diagnosing and treating the acute myelogenous leukemia.

The invention relates to the technical field of cell engineering, and particularly discloses a construction method and application of a sika deer immortalized renal epithelial cell line, and the construction method comprises the following steps: taking renal epithelial primary cells from healthy sika deer renal cortex tissues to obtain primary renal epithelial cells; treating the primary renal epithelial cells with trypsin to obtain a cell suspension; inoculating the cell suspension into a complete culture medium, and transfecting with lentivirus loaded with SV40 large T antigen genes to obtain transfected cells; 3 [mu] g / mL puromycin is applied to the transfected cells for selective culture, so that non-transfected cells are eliminated, and drug-resistant cells are obtained; carrying out continuous passage on the drug-resistant cells for at least 30 generations to obtain the immortalized renal epithelial cell line of the sika deer; according to the invention, through a specific action mechanism (inhibiting a p53 / pRb pathway and blocking cell cycle exit) of the SV40 large T antigen, a proliferation limit caused by inhibition of telomerase activity of primary cells of the cervidae animals is overcome, and a cell resource library capable of realizing continuous passage is established.

The invention relates to the technical field of antitumor drugs, in particular to a Ru (II) complex and a preparation method and application thereof, and the Ru (II) complex has a structure as shown in a formula I. The Ru (II) complex synthesized by the method disclosed by the invention not only has relatively high cytotoxicity, but also has good photodynamic antitumor activity. After the complex is illuminated, the efficiency of the complex entering cells in an active transportation mode can be accelerated, mitochondria and endoplasmic reticulum are targeted at the same time, mitochondrial membrane potential decline and endoplasmic reticulum stress are caused to form a dual organelle damage effect, immunogenic cell death is caused, the tumor microenvironment is adjusted, and the tumor cell immunogenicity is improved. The enrichment of dendritic cells (DCs) in tumor cells is realized, the chemotactic activity of effector T cells is improved, the proportion of CD4 < + > and Foxp3 < + > cell populations is reduced, and finally the anti-tumor immune response is activated. Meanwhile, the complex provided by the invention can also induce the cell to generate pan apoptosis, retard the cell cycle in the G2 / M period and enhance the effect of the complex in inhibiting tumor proliferation.

Compounds of formula (I): (I), as defined herein, and synthetic intermediates thereof, which are capable of modulating KIF18A protein thereby influencing the process of cell cycle and cell proliferation to treat cancer and cancer-related diseases. The invention also includes pharmaceutical compositions, including the compounds, and methods of treating disease states related to the activity of KIF18A.

The invention discloses an MSC culture medium composition and a culture method, and belongs to the field of biological medicine. Aiming at the problems of low MSC amplification efficiency and poor function maintenance in the prior art, the invention provides the MSC culture medium combination, which comprises a basic culture medium and functional factors, and the functional factors comprise an activation functional factor, an amplification functional factor and a steady-state functional factor which are sequentially added according to a preset time interval; wherein the activating functional factors comprise b-FGF, EGF and TGF-beta 1; the amplification functional factors comprise b-FGF (Fibroblast Growth Factor), PDGF-BB (Platelet Derived Growth Factor The steady-state functional factors comprise a b-FGF (Fibroblast Growth Factor) and IGF-1. The cell cycle is quickly started by activating the functional factors, differentiation is inhibited, and the functional factors are amplified to promote large-scale cell amplification; steady-state functional factor equilibrium amplification and dryness maintenance are carried out; and different functional factors are sequentially added according to a preset time interval, and the concentration of the factors is dynamically adjusted, so that differentiation tendency or aging acceleration caused by long-time high-concentration stimulation of a single factor is avoided, long-term efficient amplification of the MSC is realized, and the multifunctionality of the MSC is kept.

The invention belongs to the technical field of traditional Chinese medicines, and particularly relates to application of a traditional Chinese medicine composition in preparation of anti-hepatoma medicines. The traditional Chinese medicine composition comprises red ginseng, ox horn tip, musk, borneol, safflower, bezoar, radix aconiti lateralis praeparata slice, venenum bufonis, pseudo-ginseng, benzoin and pearl. Experimental results show that the traditional Chinese medicine composition can induce apoptosis and necrosis of liver cancer cells and inhibit proliferation of the liver cancer cells; and liver cancer cells are retarded to be in a G1 cell cycle. Therefore, the invention provides a new therapeutic drug for clinical treatment of liver cancer, and the raw materials are natural medicinal materials, have wide sources and have good application prospects.

The invention discloses a bacterial strain with an anti-tumor effect and application of the bacterial strain, the bacterial strain is Lactobacillus paracasei Biohalo 27, the bacterial strain is preserved in the China General Microbiological Culture Collection Center (CGMCC), and the preservation number is CGMCC NO.34917; the preservation time is June 16, 2025; the screened strain with the anti-tumor effect has the effects of inhibiting proliferation and migration of rectal cancer cells and breast cancer cells, retarding the cell cycle and promoting cell apoptosis, so that the anti-tumor purpose is achieved, and the strain can be used as a potential application value of probiotic adjuvant therapy.

The invention discloses a ganoderma lucidum lipid exosome containing a liver protection component and a preparation method and application thereof.The preparation method comprises the steps that the liver protection component is wrapped with a coarsely extracted ganoderma lucidum exosome, then the liver protection component is wrapped with lipidosome, and therefore a lipidosome-exosome-liver protection component three-layer structure is formed from outside to inside; in the three-layer structure, the outer layer liposome can protect the storage of the liver protection component and can improve the transmembrane transport efficiency, the middle layer exosome serves as a carrier and can reach a designated position to be released, and the inner layer contains the liver protection component and can improve the transmembrane transport efficiency. Cell cycle arrest can be prevented, antioxidant enzyme activity can be improved, cell membranes can be protected from oxidative damage, and redox steady state can be maintained to relieve cell aging. The prepared ganoderma lucidum lipid exosome containing the liver protection component realizes slow release synergy through a three-layer structure, and the action time of the active component is remarkably prolonged.

The invention discloses an application of 2, 3-dihydroxybenzoic acid in preparation of an antitumor drug. Researches find that 2, 3-dihydroxybenzoic acid can inhibit proliferation, migration and invasion of colorectal cancer cells in vitro and promote cell cycle arrest and cell apoptosis, and 2, 3-dihydroxybenzoic acid can inhibit growth of mouse transplanted tumors in vivo and promote cell apoptosis; the 2, 3-dihydroxybenzoic acid has a remarkable treatment effect on mouse colon cancer and can improve the immunotherapy effect; moreover, the 2, 3-dihydroxybenzoic acid small molecule substance, as an inhibitor of fatty acid synthase (FASN), plays an important role in inhibiting colorectum.

The present invention relates to the technical field of stem cell detection, and particularly relates to a determination method for purity and population doubling time of human umbilical cord mesenchymal stem cells (hUC-MSCs). The cultured hUC-MSCs are mixed with the buffer solution to obtain cell suspension; the cell suspension is mixed and incubated with a fluorescein-labeled antibody to obtain an incubated substance; and the incubated substance is centrifuged, and the precipitate obtained is cleaned and then mixed with the buffer solution to obtain a substance to be tested. The present invention analyzes cell surface markers and cell cycles by using a flow cytometer and monoclonal antibodies labeled with different fluoresceins of hUC-MSCs as well as PI staining, and further defines a determination method for purity and population doubling time of hUC-MSCs.

The present invention relates to chemical compounds having a general formula (I), as defined herein, and synthetic intermediates thereof, which are capable of modulating KIF18A protein thereby influencing the process of cell cycle and cell proliferation to treat cancer and cancer-related diseases. The invention also includes pharmaceutical compositions, including the compounds, and methods of treating disease states related to the activity of KIF18A.

The invention relates to rapamycin-loaded bionic nanoparticles as well as a preparation method and application thereof. The bionic nanoparticle loaded with the rapamycin comprises RZ NPs loaded with the rapamycin and a tumor cell membrane, the tumor cell membrane is coated with the RZ NPs loaded with the rapamycin; the rapamycin is modified in pores of the RZ NPs; and the RZ NPs has a crystal structure of ZIF8. The preparation method of the rapamycin-loaded bionic nano-particles comprises the following steps: preparing RZ NPs loaded with rapamycin, and modifying the RZ NPs by using a tumor cell membrane to prepare the RZM NPs. The RZM NPs provided by the invention has the capability of external irradiation sensitization on tumors, and due to the fact that rapamycin has potential influence possibility on cell cycles, tumor cells can be stagnated in a stage which is more sensitive to external irradiation, so that the radiotherapy effect is improved.

Metastatic uveal melanomas are highly resistant to all existing treatments. To identify actionable vulnerabilities, the inventors conducted a CRISPR-Cas9 knockout screen using a library composed of chromatin remodelers. They revealed that the histone H3 methyltransferase SETDB1 plays a critical role in metastatic uveal melanoma cell proliferation and survival. Functionally, SETDB1 knockdown triggers decreased expression of genes related to replication and cell cycle and promotes growth arrest associated with increased markers for DNA damage and senescence entry. Using pre-clinical model, they further demonstrated that anti-SETDB1 therapy tumor growth in vivo. The inventors identify SETDB1 as a new relevant therapeutic target for the treatment of metastatic uveal melanomas. The present invention relates to a method for treating uveal melanoma in a subject in need thereof comprising a step of administering said subject with a therapeutically effective amount of SETDB1 inhibitor.

The invention provides application of tea catechin in preparation of a medicine for preventing and treating bortezomib-induced peripheral neuropathy. A plurality of in-vitro model results show that tea catechin can be used as a copper death inhibitor, remarkably improves related indexes of bortezomib-induced peripheral neuropathy, improves survival rates of Schwanton cells and SH-SY5Y, improves mitochondrial functions and cell cycle abnormalities of the Schwanton cells, reduces intracellular copper ion, cuprous ion and ATP levels, and can be used for preparing the copper death inhibitor for the peripheral neuropathy of the Bortezomib-induced peripheral neuropathy of the Bortezomib-induced peripheral neuropathy. Meanwhile, the death of Schwann cells and SH-SY5Y induced by the copper death inducer is reduced. In-vivo experiments show that the tea catechin plays a role in protecting functional damage of the bortezomib, and the tea catechin remarkably improves mechanical hyperalgesia, gait abnormality and pathological changes of myelin sheath and axon of mice caused by peripheral neuropathy induced by the bortezomib. The tea catechin can be used as a medicine for peripheral neuropathy induced by bortezomib, and has high clinical application value and development prospect.

The invention relates to an application of Avasimibe in preparation of a medicine for treating nasopharynx cancer or oral cancer, and belongs to the field of tumor targeted therapy. An in-vitro cell experiment and an in-vivo animal model experiment verify the anti-tumor effect of the compound. Experiments show that Avasimibe can significantly inhibit the activity, proliferation ability, healing ability and cloning ability of nasopharynx cancer cells and oral cancer cells, can regulate cell cycle arrest in a dose-dependent manner, and induces cell apoptosis. In vivo experiments, the tumor volume of nude mice in an Avasimibe treatment group is remarkably reduced, serum cholesterol is remarkably reduced, and serum biochemical analysis shows that compared with a control group, the Avasimibe treatment group has no statistical difference in indexes such as aspartate transaminase (AST) / glutamic-pyruvic transaminase (ALT) and creatinine (Cr). The invention provides a new indication for resisting nasopharynx cancer and oral cancer for the existing compound Avassimibe, has the clinical advantages of low toxicity and capability of overcoming drug resistance, and provides a new treatment choice for patients with nasopharynx cancer and oral cancer.

The application discloses application of a reagent for detecting LRRN3 expression level in preparation of a benign prostatic hyperplasia diagnosis product. It is proved through cell function experiments and animal experiments that overexpression of the LRRN3 gene can inhibit the proliferation of prostate cells, block the cell cycle and promote cell apoptosis, thereby effectively inhibiting the prostatic hyperplasia. The discovery provides a new target and treatment strategy for the treatment of the prostatic hyperplasia, and provides a brand-new thought and method for the treatment of the prostatic hyperplasia. Based on the research results, a gene therapy drug taking the LRRN3 gene as a target can be further developed, for example, a lentivirus vector carrying the LRRN3 gene or other gene delivery systems are constructed and used for the treatment of the prostatic hyperplasia. In addition, the LRRN3 gene can be combined with other treatment methods to improve the treatment effect.

The invention belongs to the technical field of medicines, and particularly relates to application of dioscin combined with chidamide in diffuse large B-cell lymphoma. Specifically, research finds that the dioscin can significantly inhibit DLBCL cell proliferation and induce cell cycle arrest and apoptosis by up-regulating PINK1 / Parkin mediated mitochondrial autophagy and enhancing H3K27 acetylation mediated epigenetic regulation. When the chidamide and the dioscin are combined for use, a synergistic effect can be generated, and by further increasing the H3K27ac level, the cell apoptosis induction effect is enhanced, and the in-vivo and in-vitro anti-tumor activity on DLBCL is remarkably improved. The invention provides a novel and efficient DLBCL combined treatment scheme, and provides a new pharmaceutical composition and theoretical support for clinical diagnosis and treatment of DLBCL, so that the application has good practical application value.

The invention belongs to the technical field of exosomes, and discloses an exosome preparation method and application, the exosome preparation method comprises the following steps: S1, culturing target cells in an induction medium, and collecting the cells and a culture solution; s2, separating the culture solution to obtain supernate A and cell precipitate; s3, performing chromatographic purification and concentration on the supernate A to obtain the exosome; in the step S1, colchicine is also added in the process of culturing the target cells to synchronize the cell cycle; a polycaprolactone-gelatin composite microcarrier is suspended in the induction culture medium, and nicotinamide, an epidermal growth factor (EGF) and pyruvic acid are contained in the induction culture medium; the method further comprises a step S30 before the step S3, resuspending the cell precipitate obtained in the step S2 with a vesicle protection solution containing trehalose, sucrose and EDTA to obtain a supernatant B, and then combining the supernatant A with the supernatant B. According to the preparation method provided by the invention, the total secretion amount of target cells is large, the intracellular vesicle-exosome precursor can be collected, and the obtained exosome is high in concentration and low in impurity content.

The invention belongs to the technical field of biological medicines, and particularly relates to application of dirithromycin in preparation of a product for treating LINC00516 high-expression lung adenocarcinoma. The invention discloses the effect of the long-chain non-coding RNA LINC00516 in abnormal activation of the lung adenocarcinoma cell cycle for the first time. Researches show that LINC00516 is directly combined with CDK1, the kinase activity of CDK1 is remarkably enhanced, and the inhibitory phosphorylation level of CDK1 is reduced, so that lung adenocarcinoma cells are driven to quickly enter a G2 / M phase, and tumor cell proliferation is accelerated. The invention further innovatively proposes that dirithromycin is used as an intervention means, and by blocking the combination of LINC00516 and CDK1, the activity of CDK1 is effectively reduced, and the proliferation capacity of tumor cells is inhibited. In-vivo and in-vitro experiments prove that the dirithromycin can obviously inhibit the growth of lung adenocarcinoma cells with high expression of LINC00516, so that a brand-new molecular targeting treatment strategy is provided for clinic.

The invention relates to the field of plant genetic engineering, and particularly discloses a soapberry SmCYCD3; 2 gene and application thereof. The nucleotide sequence of the gene is shown as SEQ ID NO: 1, and the sequence of the protein coded by the gene is shown as SEQ ID NO: 2. Experiments show that the gene has high specificity expression in female flowers of soapberry. By heterologous overexpression of the gene in arabidopsis thaliana, typical'female promotion and male inhibition 'phenotypes such as pistil elongation, stamen number reduction and shortening, pollen viability reduction and small fruit pods of transgenic plants can be caused. Molecular mechanism studies show that: SmCYCD3; 2, performing functions by up-regulating expression of cell cycle related genes and pistil development genes AtCRC and down-regulating expression of stamen development key genes at the same time; the invention provides a key gene resource and a theoretical basis for directionally regulating and controlling the sex ratio of plant flowers through a molecular breeding means and improving the fruit yield of woody economic tree species.

This invention provides a 2-sulfonylpyrimidine-4-amide compound and its uses, belonging to the field of antitumor drug technology. The compound of this invention exhibits excellent antitumor activity targeting the colchicine site of tubulin, demonstrating antiproliferative activity against tumor cells such as HeLa, HepG2, H1299, and MCF-7 at the micromolar level, and significantly inhibiting colony formation in a dose-dependent manner. Furthermore, the compound inhibits tubulin polymerization and disrupts the microtubule network of H1299 cells in vitro, inducing cell cycle arrest in the G2 / M phase and apoptosis. More importantly, the compound can inhibit angiogenesis in HUVECs in vitro. The compound of this invention has great potential in the preparation of microtubule destabilizing agents targeting the colchicine site.

The application provides an analysis method, device and equipment based on single-cell transcriptome sequencing data, which comprises the following steps: performing quality control, downstream analysis and visual display on single-cell transcriptome sequencing expression quantitative data, performing cell filtering by using Grubbs test method to obtain effective single-cell transcriptome sequencing quantitative data, performing initialization clustering analysis on the data to obtain single-cell subgroup classification results; performing screening on the single-cell subgroup classification results to obtain target single-cell subgroups, and performing re-clustering analysis to obtain single-cell sub-subgroup classification results; performing significant difference gene screening analysis on the single-cell transcriptome sequencing quantitative data between single-cell subgroups; and performing regression analysis based on characteristic genes of cell cycles to predict cell division periods corresponding to different cell types. The application effectively solves the technical complex problems of existing single-cell transcriptome sequencing quantitative data analysis, makes data analysis more simple and reliable, and reduces the difficulty of data analysis.

The application relates to a salt type of a new cell cycle regulatory kinase inhibitor and a crystal form and a preparation method thereof, and relates to a succinate salt of a compound (6-((4-(2-(diethylamino)benzo[d]thiazol-6-yl)-5-fluoropyrimidin-2-yl)amino)pyridin-3-yl)(4-isopropylpiperazin-1-yl)methanone and a crystal form thereof, wherein two crystal forms II and III of the succinate salt are good in stability, high in solubility, and the preparation method is simple and suitable for industrial production.

The present invention provides the use of fangchinoline in preparing a drug for treating STAG2 mutation acute myeloid leukemia, and relates to the field of leukemia therapeutics. The use of fangchinoline in preparing a drug for treating STAG2 mutation acute myeloid leukemia according to the present invention addresses the problems of high incidence, poor prognosis and lack of effective drugs in STAG2 mutation acute myeloid leukemia. Fangchinoline can inhibit the proliferation and colony formation of AML cell lines SKM-1, Kasumi-6, THP-1 and U-937, induce apoptosis, cell cycle arrest and cell differentiation in these cells, and thus exert an anti-STAG2 mutation acute myeloid leukemia effect.

The invention relates to the technical field of cosmetics, in particular to a compound active peptide with functions of resisting aging and whitening skin and application of the compound active peptide. Comprising acetyl hexapeptide-1, nonapeptide-1, acetyl tetrapeptide-11, hexapeptide-9 and palmitoyl hexapeptide-12. The compound peptide disclosed by the invention can play a synergistic anti-aging and whitening role on an epidermal layer and a corium layer, and has multiple advantages; the compound peptide acts on epidermal layer keratinocytes, dermal layer fibroblasts and B16F10 cells, and can be used for detecting the senescence of the cells by influencing the expression quantity of cell senescence marker genes, influencing the cell cycle, influencing the expression quantity of extracellular matrix related proteins, influencing melanin synthesis and influencing the secretion quantity of acetylcholine in the cells. Multiple skin anti-aging and whitening effects synergistically exerted on the epidermal layer and the corium layer are achieved.

The invention belongs to the technical field of biological medicines, and particularly relates to application of cardiac glycoside medicines or pharmaceutically acceptable salts or derivatives thereof in preparation of products for inhibition, relief, adjuvant therapy or treatment of cancers and medicines. The invention provides application of cardiac glycoside drugs or pharmaceutically acceptable salts or derivatives of the cardiac glycoside drugs in preparation of products for inhibition, alleviation, adjuvant therapy or treatment of cancers and the drugs, and the cardiac glycoside drugs comprise deacetylated chaenoside, deacetylated chaenoside, deacetylated chaenoside, deacetylated chaenoside, deacetylated chaenoside, deacetylated chaenoside, deacetylated chaenoside and deacetylated chaenoside. According to the application disclosed by the invention, the effects of inhibiting, relieving, assisting in treating or treating cancers and potential mechanisms of the Deslanoside are researched in SH-SY5Y and SK-N-SH neuroblastoma cell lines, and results show that the Deslanoside can be used for inhibiting proliferation of SH-SY5Y cells and SK-N-SH cells, promoting apoptosis and respectively inducing a cell cycle to stop at a G0 / G1 phase; and G1 / S and G2 / M periods.

The invention relates to the technical field of cosmetics, in particular to a compound active peptide with skin anti-aging, anti-inflammatory and soothing functions and application of the compound active peptide. The compound active peptide is prepared from acetyl hexapeptide-1, palmitoyl tripeptide-5, acetyl dipeptide-1 cetyl ester, copper peptide and decarboxylated carnosine hydrochloride. The compound peptide acts on dermal fibroblasts, so that expression of p16 and p21 genes is reduced, and cell cycle arrest is improved; the compound acts on epidermal keratinocytes and dermal fibroblasts and inhibits COX-2 gene expression; the compound peptide acts on epidermal keratinocytes and dermal fibroblasts, and the ROS level is reduced; the compound peptide acts on PC12 cells, inhibits secretion of acetylcholine, blocks transmission of neural signals, and plays a role in immediate wrinkle removal.

The invention provides a KIF18 inhibitor and a synthesis method thereof, and particularly provides a compound shown as a formula (I), and the compound can regulate KIF18A protein, so that the cell cycle and the cell proliferation process are influenced to treat cancers and cancer-related diseases. Also provided are pharmaceutical compositions comprising the compounds and methods for treating conditions associated with KIF18A activity.

This invention discloses the application of arginine-depleted engineered bacteria for the treatment of soft tissue sarcomas, including preliminary validation, obtaining qualified engineered bacteria SGR1, obtaining drug compositions and regimens, experimental conclusions, and clinical application promotion. During use, clinical soft tissue sarcoma samples are collected, including undifferentiated pleomorphic sarcoma, synovial sarcoma, and liposarcoma. Immunohistochemistry (IHC) is used to detect ASS1 protein expression, qPCR is used to detect ASS1 gene transcription levels, and the proportion of ASS1 deletion / low expression is statistically analyzed. Arginine auxotrophic sarcoma subpopulations are confirmed based on literature. Cells are cultured in arginine-containing or arginine-free media, and cell viability, colony formation, cell cycle, and apoptosis are detected. The sensitivity of ASS1-deficient cells to arginine deprivation is verified, and therapeutic targets are identified. The enzyme activity, substrate specificity, and immunogenicity of human ARG I / II, mycoplasma ADI, and Pseudomonas ADI are compared. High-activity, low-immunogenic enzymes or enzyme combinations (such as human ARG I + microbial ADI) are selected, and site-directed mutagenesis or codon optimization is performed on microbial ADI to increase expression levels.